DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION				
12420 Parklawn Drive, Room 2032	10/30/2023-11/3/2023				
Rockville, MD 20857	FEINUMBER 3001581899				
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED					
Kenneth V. Meade, Senior Compliance Specialist					
FIRM NAME	STREET ADDRESS				
Contract Pharmaceuticals Limited Canada	7600 Danbro Crescent				
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED				
Mississauga, L5N 6L6	Contract Manufacturer				

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

## DURING AN INSPECTION OF YOUR FIRM I OBSERVED:

## **OBSERVATION 1**

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

Specifically, your firm was notified a highly pathogenic microorganism was recovered during environmental monitoring of the production area and an incident report (IR) was not initiated to conduct a documented investigation of the result. Brucella melitensis was recovered from an air sample taken on 08/02/2022 in Wash Up Room where production equipment is cleaned. Firm procedure QC-250-24 Microbial Environmental Monitoring (EM) Program does not require IRs to be initiated when action levels are not reached and lacks instructions to initiate an IR for pathogenic or objectionable microbial recoveries. Quality Unit personnel approved both the Report and 2022 Environmental Monitoring Annual Trend Report which included the recovery of Brucella melitensis. The 2022 Environmental Monitoring Annual Trend Report states Brucella melitensis is considered non-objectionable, however the identification report from your third-party contract laboratory received by your Quality Unit on 08/24/2022 states the microorganism is highly pathogenic.

SEE REVERSE OF THIS PAGE		Investigator	Kidena L Corroy Interplate Signed By Kristina L. Corroy -S Date Signed: 11-03-2023 99:22-55	DATE ISSUED 11/3/2023
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATION	ONS	PAGE 1 of 1 PAGES